Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT02959463 | Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma | completed | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2026 |
| clinicaltrials |
| NCT03611595 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | Peter ZageOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05181462 | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.(TRIFOUR) | completed | Phase 1 / Phase 2 | 117 | Cantargia ABINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06266143 | A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 71 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06619873 | A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects | completed | Phase 1 | 24 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03820817 | Rifaximin in Patients With Monoclonal Gammopathy | completed | Phase 1 | 50 | Emory UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04088864 | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | completed | Phase 1 | 10 | Kara Lynn DavisOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02308072 | Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer(ORCA-2) | completed | Phase 1 | 16 | University College, LondonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03336606 | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04846920 | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) | completed | Phase 1 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT01823562 | Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04915612 | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05301764 | A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 39 | Lyvgen Biopharma Holdings LimitedINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05534620 | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | completed | Phase 1 | 20 | medac GmbHINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05900986 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Integro TheranosticsINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT02493530 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | completed | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04130542 | Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy | completed | Phase 1 | 105 | Lyvgen Biopharma Holdings LimitedINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04635995 | Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy | completed | Phase 1 | 66 | Lyvgen Biopharma Holdings LimitedINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05564650 | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06713564 | A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer | completed | Phase 1 | 24 | Integro TheranosticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT00911118 | Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer | completed | Phase 1 | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04742101 | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 57 | Institut de Recherches Internationales ServierOTHER | 6 | May 18, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | completed | Phase 1 / Phase 2 | 98 | BioXcel Therapeutics IncINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 190 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT01334073 | Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors(EVAX) | completed | Phase 1 | 19 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05779163 | A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors | completed | Phase 1 / Phase 2 | 26 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07454863 | A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) | completed | Phase 1 | 6 | Dizal PharmaceuticalsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT02797795 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | completed | Phase 1 | 78 | Neovia Oncology Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)(UNIVERSAL) | completed | Phase 1 | 73 | Allogene TherapeuticsINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | completed | Phase 1 / Phase 2 | 225 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04640545 | A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | completed | Phase 1 | 79 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04687761 | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | completed | Phase 1 / Phase 2 | 113 | PETHEMA FoundationOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT02437227 | Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833(PanRAF) | completed | Phase 1 | 31 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03017807 | Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT03758287 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | completed | Phase 1 / Phase 2 | 108 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT04619056 | First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma | completed | Phase 1 | 21 | CEBIOTEXINDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT05038839 | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | completed | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05162755 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | completed | Phase 1 | 41 | Institut de Recherches Internationales ServierOTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT05076396 | PM14 Administered Intravenously to Patients With Advanced Solid Tumors | completed | Phase 1 | 126 | PharmaMarINDUSTRY | 3 | May 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2026source: clinicaltrials